Inserm U954, Department of Hepato-Gastroenterology, University Hospital of Nancy, Université Henri Poincaré 1, Vandoeuvre-lès-Nancy, France.
Departemental of Hepato-Gastroenterology, University Hospital of Saint Etienne, France.
J Crohns Colitis. 2014 Feb;8(2):161-5. doi: 10.1016/j.crohns.2013.08.004. Epub 2013 Aug 30.
In patients with inflammatory bowel disease (IBD) tolerating 2-h infusions of 5mg/kg infliximab scheduled maintenance therapy, the infusion time can be shortened to 1-h with good tolerability. A retrospective study with small sample size demonstrated the feasibility of 1-hour infusion time for 10mg/kg infliximab in IBD patients.
Between November 2011 and July 2012, 63 patients received 1-hour 10mg/kg infliximab infusions under standard operating procedures and were enrolled in a prospective observational study. Intravenous steroid premedication was given to all patients.
Sixty-three IBD patients on infliximab maintenance therapy (43 Crohn's disease, 34 males) received 1-hour 10mg/kg infusions during the study period. A total of 182 infliximab infusions were administered. Seventeen (26%) patients were receiving concomitant immunomodulators. Two patients experienced (2/182, 1%) severe acute infusion reactions consisting on a cutaneous lupus and one severe anaphylactic reaction. We also observed one (1/182, 0.5%) severe delayed reaction after the first 1-hour infliximab infusion consisting on acne generalis. All 3 reactions led to infliximab discontinuation. No mild acute reactions and 6 mild delayed reactions (6/182, 3%) occurred.
In patients with IBD receiving infliximab scheduled maintenance therapy, 1-hour infusion time for 10mg/kg infliximab seems to be well tolerated. This option might be considered in clinical practice in order to decrease the extra-burden of infliximab infusions in this patient population.
在能够耐受 5mg/kg 英夫利昔单抗 2 小时输注的炎症性肠病（IBD）患者中，可将输注时间缩短至 1 小时，且具有良好的耐受性。一项小样本量的回顾性研究表明，IBD 患者使用 10mg/kg 英夫利昔单抗进行 1 小时输注是可行的。
2011 年 11 月至 2012 年 7 月，63 例患者根据标准操作规程接受了 1 小时 10mg/kg 英夫利昔单抗输注，并纳入了一项前瞻性观察性研究。所有患者均给予静脉类固醇预治疗。
63 例 IBD 患者（43 例克罗恩病，34 例男性）在研究期间接受了英夫利昔单抗维持治疗 1 小时 10mg/kg 输注。共输注英夫利昔单抗 182 次。17 例（26%）患者同时接受免疫调节剂治疗。2 例（2/182，2%）患者发生严重急性输注反应，包括皮肤狼疮和 1 例严重过敏反应。我们还观察到首次 1 小时英夫利昔单抗输注后 1 例（1/182，0.5%）严重迟发性反应，表现为全身痤疮。所有 3 例反应均导致英夫利昔单抗停药。发生轻度急性反应 6 例（6/182，3%），无迟发性反应。
在接受英夫利昔单抗维持治疗的 IBD 患者中，10mg/kg 英夫利昔单抗 1 小时输注时间似乎具有良好的耐受性。在这种患者人群中，为了减少英夫利昔单抗输注的额外负担，该方案可能在临床实践中得到考虑。
